Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of RTA 408 in Mitochondrial Myopathy
2014-003501-15Phase 2Completed
- Sponsor
- Reata Pharmaceuticals
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of omaveloxolone in Mitochondrial myopathies (MM), sponsored by Reata Pharmaceuticals. Primary endpoint: Change from baseline in peak work during maximal exercise testing. Started Dec 2014; status: completed.
02
Drugs
omaveloxolone
03
Conditions
Mitochondrial myopathies (MM)
Beyond the preview
Go deeper on 2014-003501-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003501-15.